相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
详询
- 保质期:
详询
- 库存:
50
- 供应商:
广州市左克生物
- 规格:
1tube/3tubes
| 规格: | 1tube | 产品价格: | ¥1754.0 |
|---|---|---|---|
| 规格: | 3tubes | 产品价格: | ¥3980.0 |
产品简介:
品牌:DOJINDO/东仁
货号:F374
产品名称:细胞二价铁离子检测探针—FerroOrange
特点:
● 荧光法高敏检测胞内二价铁
● 适合于多种检测仪器
● 铁死亡常见指标之一
关联检测指标
铁离子检测丨从实验思路到检测指标 PDF下载
| 关联指标干货参考(点击查看) | 检测指标(点击查看) | |
|
铁离子与铁死亡 -细胞(不同仪器检测方法) -组织和活体斑马鱼幼体(不同样本检测方法) |
FerroOrange | |
| Iron Assay Kit -Colorimetric- | ||
| Mito-FerroGreen | ||
|
铁自噬 |
铁死亡与线粒体自噬 | Mitophagy Detection Kit |
| 细胞自噬 | DALGreen | |
| DAPGreen | ||
| DAPRed | ||
|
铁死亡与脂质过氧化物 |
Liperfluo | |
| MitoPeDPP | ||
| MDA Assay Kit | ||
| 亚铁离子检测与肝功能 | Lipi-Blue/Green/Red/Deep Red | |
| Lipid Droplet Assay Kit-Blue/Deep Red | ||
| Fatty Acid Uptake Assay Kit | ||
*点击即可跳转至详情页
规格性状
性状:可溶于乙腈,甲醇和二甲基亚砜。
纯度(HPLC):92.0%以上
荧光光谱:符合一致性
产品概述
铁是生物体内最丰富的过渡金属元素,它参与各种生理过程活动。 近年来,活细胞中的游离铁受到广泛关注, 游离铁最常以其稳定的氧化还原态存在,即亚铁离子 (Fe2+) 和铁离子 (Fe3+)。对研究者来说,在研究细胞内的还原环境,金属转运蛋白和Fe2+的水溶性时,了解Fe2+的行为比了解Fe3+的行为更为重要。FerroOrange作为一种新型的荧光探针,可对活细胞内的Fe2+进行荧光成像。FerroOrange和Fe2+反应后的荧光强度上升不可逆,与Fluo-3(货号:F019)这类可以实时监测钙离子的荧光探针有所不同。
原理

FerroOrange检测胞内Fe2+

图为将2 μl的1 mmol/l FerroOrange和2 μl的10 mmol/l的各种金属离子添加到1 ml的50 mmol/l HEPES缓冲液(pH 7.4)中,并在室温下反应1小时后测量的荧光强度。
荧光特性

Ex:543 nm Em:580 nm
铁离子试剂的选择
| FerroOrange | Mito-FerroGreen | |
| 存在部位 | 细胞内 | 线粒体 |
| 荧光特性 | λex : 543 nm、λem : 580 nm | λex : 505 nm、λem : 535 nm |
| 检测仪器 | 荧光显微镜、荧光酶标仪(Cy3) | 荧光显微镜(FITC、GFP) |
| 测定对象 | 活细胞 | 活细胞 |
| 检测次数 | 24μg可染色17次35mm dish (终浓度为1μmol/l) |
50μg可染色5次35mm dish (终浓度为5μmol/l) |
与其他染料共染
FerroOrange与各种细胞内的染色试剂共染
用各种染色试剂染色HeLa细胞,清洗细胞。然后将FerroOrange添加到细胞中,并用荧光显微镜观察。
与ER染色试剂共染
<检测条件>
FerroOrange: Ex: 561 nm、Em: 570-620 nm
ER Tracker Green(ER染色试剂): Ex: 488 nm、Em: 510-555 nm
标尺: 10 μm

与线粒体染色试剂共染
<检测条件>
FerroOrange: Ex: 561 nm、Em: 570-620 nm
MitoBright Deep Red(线粒体染色试剂): Ex: 640 nm、Em: 650-700 nm
标尺: 10 μm

与高尔基体染色试剂的共染
<检测条件>
FerroOrange: Ex: 561 nm、Em: 570-620 nm
BODIPY FL(高尔基体染色试剂): Ex: 488 nm、Em: 510-555 nm
标尺: 10 μm

操作步骤
1.细胞接种于荧光培养皿中,在37℃,5% CO2培养箱中孵育过夜。
2.弃去上清液,并用HBSS或无血清培养基洗涤细胞3次。
3.更换含有药物的培养基,在37℃,5% CO2培养箱中孵育。
* 请根据药物特性优化孵育时间。
4.加入浓度为1 μmol/l的FerroOrange工作液,在37℃,5% CO2培养箱中孵育。
* 加入FerroOrange染色剂后请立即观察,不要洗涤。
5.在荧光显微镜下观察细胞。
高灵敏度检测胞内铁离子
使用HeLa细胞,通过FerroOrange确认细胞内Fe2+的变化
与对照组的细胞相比,用硫酸亚铁 (II) 铵处理的HeLa细胞的FerroOrange荧光强度增加。 相反,在用Bpy处理的细胞中,其荧光强度降低。
因此,证明FerroOrange与细胞内Fe2+反应。
A: 对照组
B: 铁剂·硫酸亚铁(II) 铵(终浓度100umol/l)处理
C: 铁螯合剂·2,2'-Bipyridyl (Bpy)(终浓度100umol/l)处理

检测条件 Ex/Em = 561 nm/570-620 nm 比例尺:20 μm
使用流式细胞仪检测
通过流式细胞仪进行定量分析
——FerroOrange的荧光强度可能受细胞密度和细胞种类的影响
——培养基的更换和清洗可能使染料从细胞内泄露
——进行流式定量分析时,需优化实验步骤

1. HeLa cells (1 x105 cells/well) in MEM (10% fetal bovine serum, 1% penicillin-streptomycin) were seeded on a 6 well plate and were cultured at 37oC in a 5% CO2 incubator overnight.
2. The cells were washed with serum-free medium (2 mL) three times. Then, serum-free medium (1 mL) was added to the cells.
3. 10 mmol/L Ammonium iron (II) sulfate (10 μL) was added to wells (The final concentration: 100 μmol/L).
4. To mix Ammonium iron(II) sulfate and serum-free medium, the entire medium was pipetted up from wells and then immediately pipetted back one time.
5. The cells were incubated for 20 min in a 37oC incubator equilibrated with 95% air and 5% CO2, and the cells were washed with HBSS (1 mL) three times.
6. After trypsinization (250 µL), stop the reaction with serum medium (1 mL), 1.25 ml of the cell suspension was transferred to a microcentrifuge tube.
7. The cells suspension was centrifuged at 1,500 rpm for 3 minutes.
8. The supernatant was discarded and HBSS (1 mL) was added to the microcentrifuge tube and suspended by pipetting.
9. The cells suspension was centrifuged at 1,500 rpm for 3 minutes and the supernatant was discarded.
10. 1 μmol/L FerroOrange in MEM (serum-free medium) (300 μL) was added to the cells.
11. The cells were incubated for 15 -30 min in a 37oC incubator equilibrated with 95% air and 5% CO2.
12. The stained cells were passed through a cell strainer and analyze samples using a flow cytometer.
<注意点>
1.清洗对于结果分析的影响

2.染料体积对于结果分析的影响

常见问题Q&A
|
Q1:FerroOrange由于是活细胞荧光探针,如果铁死亡发生,导致细胞膜破裂后,荧光是否存在? |
|
A1:由于FerroOrange是活细胞探针,对死细胞无法发挥出探针的正常性能。 |
|
Q2: FerroOrange只会检测游离铁吗?还是某些如铁硫蛋白里的结合铁,都可以检测吗? |
|
A2:FerroOrange只检测游离的二价铁 |
|
Q3: 铁死亡研究中,Fe2+和Fe3+的检测哪个更重要。铁死亡的时候,总Fe都会变吗?还是说只有Fe2+/Fe3+之间的转化。 |
|
A3:二价铁作为线粒体的所需物质在细胞质的“铁池”内积蓄,它在DNA合成,细胞周期调控,线粒体内ATP的产生等起重要作用。为了防止损伤细胞,多余的二价铁会与铁蛋白结合生成没有氧化还原性的三价铁并储存。或者通过膜铁转运蛋白排出到细胞外。 |
|
Q4: FerroOrange能否用于固定处理之后的样本? |
|
A4:不能用于石蜡切片。 试剂能尝试于温和条件下固定处理之后的样本,如多聚 甲醛(PFA,终浓度3%)在4°C中培养10 min。与未固定的样本相比,固定20 min以上或室温固定后的样本的荧光强度会明显降低。请注意本探针可能很难于固定样本中使用,必须先进行染色,然后做尝试。 |
|
Q5:本探针适合于什么检测方式? |
|
A5:见表格
我们建议使用绿色激光(Ex:532 nm)激发FerroOrange |
|
Q6:染色时需要注意什么? |
|
A6:注意如下, 1.FerroOrange染色后的对培养基的更换。 染色后无需清洗工作液,通常血清中含有铁离子,请注意使用不含血清的培养基,所以染色后即使细胞外有残留的FerroOrange,但是因为细胞外没有血清中铁离子的影响,也不会产生背景荧光的问题。
2.对照实验。 为了检查铁检测的实验条件,我们建议准备加入铁螯合试剂Bpy(2,2`-bipyridine)或铁(硫酸铵铁(II))的样品,并观察FerroOrange荧光强度的变化。
3.细胞难以染色(灵敏度低)时的办法。 根据细胞种类的不同,染色程度也有差异。 使FerroOrange working solution浓度高于推荐的1 µmol/l进行染色。建议在1-5 µmol/l范围内染色。 |
|
Q7:使用荧光酶标仪的操作步骤 |
|
A7:请参考下面的实验例子进行测量。 <测定样品>。 样品A:无添加剂(仅HeLa细胞)。 样品B:添加了铁螯合试剂2,2`-bipyridyl(Bpy)的HeLa细胞。 样品C:添加铁(硫酸铵铁)的HeLa细胞。 <测量操作>。 1.在96孔黑板(透明底)上接种100 µl HeLa细胞悬液,使其达到10,000 cells/well,在37℃ 5%CO2 培养箱中过夜培养。 2.样品C的细胞用MEM(不含FBS)100 µl洗涤3次。 3.向样品C中添加100 μl硫酸铵铁(II)/MEM(不含FBS) (最终浓度: 100 µmol/l),在37℃ 5%CO2培养箱中静置30分钟。 4.用100 µl HBSS洗涤所有孔的细胞3次。 5.向样品A和C中添加100 μl的1 µmol/l FerroOrange working solution ,向样品B中添加100 μl含有FerroOrange(最终浓度:1 µmol/l)和Bpy(最终浓度:100 µmol/l)的HBSS溶液,在37℃ 5%CO2培养箱中培养30分钟。 6.用多功能读板器检测各样品的荧光强度(Ex:543 nm,Em:580 nm)。
|
|
Q8:推荐的滤光片 |
|
A8: 激发滤光片:530-565 nm 发射滤光片:570-620 nm |
| Q9:FerroOrange能用于固定细胞吗 |
| A9:固定后会测不到FerroOrange的信号,不能确认正常细胞内铁离子的变化,所以不建议使用固定细胞。 ( 参考 ) 向HepG2细胞里加入硫酸亚铁铵(II)(终浓度:100 μmol/l),分别做不固定处理、15分钟固定处理或30分钟固定处理,再加入FerroOrange Working solution,用荧光显微镜观察。
|
|
Q10:可以使用悬浮细胞吗 |
|
A10:可以,请参照以下案例。 【实验例】 Jurkat細胞里添加硫酸亚铁铵(II)(终浓度:100 μmol/l),再加入FerroOrange Working solution,用荧光显微镜观察
<实验步骤> ① 将 3×106cells/ml 的Jurkat细胞悬浮液(使用无血清MEM)放置到培养皿中,加入 10mmol/l 硫酸亚铁铵(II)溶液(终浓度 100µmol/l)。 ② 在培养箱内(37℃、5%CO2存在下)培养 30 分钟。 ③ 移到1.5ml tube离心,除去上清后用HBSS洗涤1次。 ④ 离心除去上清后,加入 1µmol/l FerroOrange working solution,移到 ibidi 8-well plate。 ⑤ 在培养箱内(37℃、5%CO2存在下)培养30分钟。 ⑥ 荧光显微镜观察。 |
|
Q11:信噪比(S/N)比较小,考虑到的原因有什么? |
|
A11:考虑血清的影响。 使用含血清培养基时,相较于无血清培养基背景升高。 (参考) 10µM Erastin处理24小时后的A549细胞里,用血清培养基和无血清培养基分别做对比,再加入FerroOrange Working solution,用荧光显微镜进行了观察。
|
参考文献
| 编号 | 文献 | 年 | IF |
| 1 | Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis,Nat Neurosci. 2021 Jul;24(7):1020-1034. | 2021 | 28.8 |
| 2 | Maintaining Iron Homeostasis Is the Key Role of Lysosomal Acidity for Cell Proliferation, Molecular Cell, 2020, 77(3), 645-655.e7 |
2020 | 19.3 |
| 3 | Breaking the Iron Homeostasis: A “Trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition,ACS Nano. 2022 Aug 23;16(8):12786-12800. | 2022 | 18.0 |
| 4 | N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer,Nat Commun . 2022 May 13;13(1):2672. |
2022 | 17.7 |
| 5 | Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy,Adv Sci (Weinh). 2022 Jun;9(17):e2105451. | 2022 | 17.5 |
| 6 | The role of ferroptosis mediated by NRF2/ERK-regulated ferritinophagy in CdTe QDs-induced inflammation in macrophage,J Hazard Mater. 2022 Aug 15;436:129043. | 2022 | 14.2 |
| 7 | Copper-dependent autophagic degradation of GPX4 drives ferroptosis,Autophagy. 2023 Jan 12;1-15. | 2023 | 13.3 |
| 8 | Development of non-adherent cell-enclosing domes with enzymatically cross-linked hydrogel shell,Biofabrication. 2022 Oct 27;15(1). | 2022 | 11.1 |
| 9 | Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation,Redox Biol . 2021 May;41:101942. | 2021 | 10.8 |
| 10 | BRCA1 haploinsufficiency promotes chromosomal amplification under Fenton reaction-based carcinogenesis through ferroptosis-resistanceR,Redox Biol. 2022 Aug;54:102356. | 2022 | 10.8 |
| 11 | Poly(rC)-binding protein 1 represses ferritinophagy-mediated ferroptosis in head and neck cancer,Redox Biol . 2022 May;51:102276. | 2022 | 10.8 |
| 12 | Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma,ACS Appl Mater Interfaces . 2023 Jan 25. | 2023 | 10.4 |
| 13 | PM2.5 induces ferroptosis in human endothelial cells through iron overload and redox imbalance,Environmental Pollution, 2019, | 2019 | 10.0 |
| 14 | β-hydroxybutyrate inhibits ferroptosis-mediated pancreatic damage in acute liver failure through the increase of H3K9bhb,Cell Rep. 2022 Dec 20;41(12):111847. | 2022 | 10.0 |
| 15 | LncRNA HEPFAL accelerates ferroptosis in hepatocellular carcinoma by regulating SLC7A11 ubiquitination,Cell Death Dis . 2022 Aug 25;13(8):734. | 2022 | 9.7 |
| 16 | Inhibiting multiple forms of cell death optimizes ganglion cells survival after retinal ischemia reperfusion injury,Cell Death Dis . 2022 May 30;13(5):507. |
2022 | 9.7 |
| 17 | Phenazine derivatives attenuate the stemness of breast cancer cells through triggering ferroptosis,Cellular and Molecular Life Sciences,2022,79, 360 | 2022 | 9.2 |
| 18 | 3D two-photon brain imaging reveals dihydroartemisinin exerts antiepileptic effects by modulating iron homeostasis,Cell Chem Biol . 2022 Jan 20;29(1):43-56.e12. |
2022 | 9.1 |
| 19 | PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway,Cell Death Differ . 2022 Oct;29(10):1982-1995. | 2022 | 8.0 |
| 20 | Combined treatment of polygonatum and Scutellaria baicalensis suppresses lung cancer cell proliferation through inducing ferroptosis,PHYTOMEDICINE,2023, | 2023 | 7.9 |
| 21 | Treatment with the Ferroptosis Inhibitor Ferrostatin-1 Attenuates Noise-Induced Hearing Loss by Suppressing Ferroptosis and Apoptosis,Oxid Med Cell Longev . 2022 Dec 7;2022:3373828. | 2022 | 7.3 |
| 22 | The TBX1/miR-193a-3p/TGF-β2 Axis Mediates CHD by Promoting Ferroptosis,Oxid Med Cell Longev . 2022 Jan 7;2022:5130546. | 2022 | 7.3 |
| 23 | Discovery of novel diphenylbutene derivative ferroptosis inhibitors as neuroprotective agents,Eur J Med Chem . 2022 Mar 5;231:114151. | 2022 | 7.1 |
| 24 | FDX1 regulates leydig cell ferroptosis mediates PM2.5-induced testicular dysfunction of mice,Ecotoxicology and Environmental Safety,2023, | 2023 | 6.8 |
| 25 | The RSL3 Induction of KLK Lung Adenocarcinoma Cell Ferroptosis by Inhibition of USP11 Activity and the NRF2-GSH Axis,Cancers (Basel) . 2022 Oct 25;14(21):5233. |
2022 | 6.6 |
| 26 | Identification and validation of a ferroptosis-related gene to predict survival outcomes and the immune microenvironment in lung adenocarcinoma,Cancer Cell Int. 2022 Sep 24;22(1):292. | 2022 | 6.4 |
| 27 | CHAC1 as a Novel Contributor of Ferroptosis in Retinal Pigment Epithelial Cells with Oxidative Damage,Int J Mol Sci . 2023 Jan 13;24(2):1582. | 2023 | 6.2 |
| 28 | MiR-7-5p is a key factor that controls radioresistance via intracellular Fe2+ content in clinically relevant radioresistant cells, Biochemical and Biophysical Research Communications, 2019, |
2019 | 3.3 |
| 29 | Synergistic antitumor efficacy of gemcitabine and cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via Sp1-SAT1-polyamine metabolism pathway,CELLULAR ONCOLOGY, 2023, | 2023 | 6.6 |
| 30 |
Ferritin was involved in interleukin-17A enhanced osteogenesis through autophagy activation, Int Immunopharmacol,2023,doi.org/10.1016/j.intimp.2023.110916 |
2023 | 5.6 |
| 31 | Improving lysosomal ferroptosis with NMN administration protects against heart failure ,Life Science Alliance,2023, | 2023 | 4.4 |
| 32 | Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation,Redox Biology,2023, | 2023 | 11.4 |
| 33 | Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced
Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma |
2023 | 9.5 |
| 34 | 7-Dehydrocholesterol dictates ferroptosis sensitivity | 2024 | 64.8 |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验合成后进行,催化此过程的肽基脯氨酸羟化酶需要二价铁离子,可被铁离子络合剂的a′-dipyridyl 所抑制。肽的脯氨酸羟化后,细胞器的糖链结合,被分泌到细胞外,纳入细胞壁中。
) ferrooxid-ans为 1954年发表的铁细菌,在酸性条件下可氧化二价铁和固定二氧化碳。该菌也可利用硫和无机硫化物。生长的最适 pH为 2.5-4.0左右。氧化铁离子时,必须要求硫酸,其反应为: 4FeSO4 O2 2H2 SO4 → 2Fe2 ( SO4 ) 3 2H2 O 电子传递系统为细胞色素 a, b, c, c1 等。二价铁离子由细胞色素 c还原酶还原细胞色素 c而生成三价铁离子。在电子传递系统中生成 ATP,由 ATP电子逆流还原 NAD进行二氧
影响。 CYP参与药物代谢的总反应式可用式表达: DH+NADPH+[H+]+O2→DOH+H2O+[NADP+] 含铁离子的P450与药物分子结合,接受从NADPH—P450还原酶传递来的一个电子,使铁转变为二价亚铁离子;随之与一分子氧、一个质子、第二个电子结合,形成Fe2+OOH●DH复合物,它与另一个质子结合,产生水和铁氧复合物(FeO)3+●DH。(FeO)3+●与氢原子(来自DH)分离,形成一对短暂的自由基,氧化型药物从复合物中释放
技术资料暂无技术资料 索取技术资料












